VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $529,750 | -22.9% | 32,500 | 0.0% | 0.01% | -14.3% |
| Q2 2023 | $687,050 | +5.3% | 32,500 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $652,600 | -26.5% | 32,500 | -4.4% | 0.01% | -30.0% |
| Q4 2022 | $888,420 | +117.2% | 34,000 | -15.0% | 0.01% | +100.0% |
| Q3 2022 | $409,000 | +119.9% | 40,000 | -10.1% | 0.01% | +150.0% |
| Q2 2022 | $186,000 | -22.5% | 44,500 | -7.3% | 0.00% | -33.3% |
| Q1 2022 | $240,000 | -25.7% | 48,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $323,000 | +47.5% | 48,000 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $219,000 | -20.1% | 40,000 | -4.5% | 0.00% | 0.0% |
| Q2 2021 | $274,000 | -21.7% | 41,900 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $350,000 | -49.5% | 41,900 | -57.7% | 0.00% | -63.6% |
| Q4 2020 | $693,000 | +27.2% | 98,951 | +13.2% | 0.01% | +22.2% |
| Q3 2020 | $545,000 | -0.4% | 87,385 | -25.2% | 0.01% | -10.0% |
| Q2 2020 | $547,000 | +53.2% | 116,810 | +34.7% | 0.01% | +42.9% |
| Q1 2020 | $357,000 | – | 86,730 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |